Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $106.20 Average Price Target from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned a consensus rating of “Hold” from the twenty-two brokerages that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $106.20.

A number of analysts have weighed in on ZBH shares. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Robert W. Baird reissued a “neutral” rating and set a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Barclays lowered their target price on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a report on Thursday, February 12th. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Finally, William Blair began coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They set a “market perform” rating for the company.

Zimmer Biomet Stock Down 0.2%

Shares of ZBH opened at $90.82 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $92.24 and a two-hundred day moving average price of $93.77. The stock has a market cap of $17.77 billion, a price-to-earnings ratio of 25.66, a P/E/G ratio of 1.86 and a beta of 0.61. Zimmer Biomet has a 12 month low of $84.59 and a 12 month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. The company had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company’s revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts predict that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is 27.12%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the business. Advisortrust Partners LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $442,000. Corient Private Wealth LLC raised its holdings in shares of Zimmer Biomet by 11.5% in the fourth quarter. Corient Private Wealth LLC now owns 46,989 shares of the medical equipment provider’s stock valued at $4,230,000 after buying an additional 4,863 shares during the last quarter. Auto Owners Insurance Co raised its holdings in shares of Zimmer Biomet by 8,892.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock valued at $180,713,000 after buying an additional 1,987,362 shares during the last quarter. Pacer Advisors Inc. lifted its position in Zimmer Biomet by 4,020.2% during the 4th quarter. Pacer Advisors Inc. now owns 697,753 shares of the medical equipment provider’s stock worth $62,742,000 after buying an additional 680,818 shares in the last quarter. Finally, Monetary Solutions Ltd acquired a new position in Zimmer Biomet during the 4th quarter worth about $30,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.